ArticleMicrosystems & nanoengineering2025
High-precision transdermal drug delivery enabled by a dual-pump parallel valveless piezoelectric micropump integrated with hollow microneedles.
Article in Microsystems & nanoengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Skin Barrier-Informed Topical and Transdermal Drug Delivery: Excipient-Driven Strategies, Vehicle Transformation, and Translational Challenges.Pharmaceutics · 2026Review
- Optimizing snake fang-inspired microneedles for transdermal liquid drug delivery.Drug delivery and translational research · 2026Article
- Skin-like micropumps transform human motion into fluidic flow via morphing valves.Microsystems & nanoengineering · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Transdermal drug delivery (TDD) system based on piezoelectric micropumps is a novel route of drug delivery that is wearable and highly patient-compliant. The advantage of valveless micropumps, such as their simple structure, high reliability and low cost, have been investigated in comparison to valve-based micropumps. However, the flow pulsation and backflow effect of valveless pump can reduce the controllability and precision of the system. Here, a TDD wearable device integrated with a dual-pump parallel valveless piezoelectric micropump and hollow microneedle array is presented, which is fabricated by means of 3D printing technology. The simulation analysis and experimental results indicate that the dual-pump parallel micropump with asynchronous driving can achieve a full forward flow and reduces the influence of flow pulsation on the system's stability, showing the excellent controllability and high precision of the device. The output flow rate and pressure of the micropump can be controlled by the driving signal, which are about 1.61 mL/min and 700 Pa with the sine driving signal of 40 V, 600 Hz. Through animal experiments, we demonstrate that the device can successfully deliver insulin to mice and control blood glucose. In conclusion, this TDD device which potentially provides low-cost and high-precision results than existing technologies, shows considerable promise in wearable drug delivery applications, especially in managing chronic diseases that require long-term treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.